Clinical Trials Logo

Osteosarcoma clinical trials

View clinical trials related to Osteosarcoma.

Filter by:

NCT ID: NCT06217003 Not yet recruiting - Osteosarcoma Clinical Trials

Trilaciclib Combined With Chemotherapy for Perioperative Treatment of Osteosarcoma

Start date: February 1, 2024
Phase: Phase 2
Study type: Interventional

This study is a prospective, single arm phase II study aimed at evaluating the efficacy and safety of trilaciclib before perioperative chemotherapy in patients with osteosarcoma.

NCT ID: NCT06171282 Recruiting - Sarcoma Clinical Trials

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors

Start date: July 12, 2023
Phase: Early Phase 1
Study type: Interventional

9 participants are expected to be enrolled for this open,Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced bone and soft tissue tumors.

NCT ID: NCT06162962 Completed - Osteosarcoma Clinical Trials

Oncological and Functional Outcomes in Lower Limb Osteosarcoma Pediatric Patient

Start date: January 1, 2000
Phase:
Study type: Observational

Retrospective analysis of specific characteristics of complications and long-term oncological and function outcomes in lower-limb osteosarcoma pediatric patients.

NCT ID: NCT06156410 Recruiting - Osteosarcoma Clinical Trials

Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma

Start date: October 24, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to better understand how safe and effective the drug cabozantinib in combination with high-dose ifosfamide is in the treatment of children and adults with relapsed/refractory Ewing sarcoma and osteosarcoma.

NCT ID: NCT06129903 Recruiting - Sarcoma Clinical Trials

Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With Sarcoma

Start date: November 7, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the feasibility of early access to mental healthcare during sarcoma treatment as well as to assess the association between early access to psychiatric care and depression, anxiety, postoperative outcomes, and patient satisfaction in patients undergoing surgery for musculoskeletal sarcoma.

NCT ID: NCT06125171 Not yet recruiting - Osteosarcoma Clinical Trials

Tucidinostat Plus Apatinib for Advanced Osteosarcoma

Start date: January 2024
Phase: Phase 2
Study type: Interventional

This phase II study was designed to assess the efficacy and safety of the combination of Apatinib, Tucidinostat (chidamide), a histone deacetylase inhibitor in relapsed or refractory osteosarcoma patients.

NCT ID: NCT06117878 Recruiting - Soft Tissue Sarcoma Clinical Trials

Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma

Start date: September 1, 2022
Phase: Early Phase 1
Study type: Interventional

This study will evaluate the safety and efficacy of NK510 in the treatment of Osteosarcoma and Soft Tissue Sarcoma.NK510 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated.

NCT ID: NCT06114225 Recruiting - Osteosarcoma Clinical Trials

Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial

PROMIS
Start date: June 1, 2023
Phase: Phase 2
Study type: Interventional

The aim of this study is to evaluate the efficacy and safety of pre-operative concurrent Stereotactic Body Radiotherapy (SBRT) and and programmed cell death protein-1 (PD-1) blockade immunotherapy followed by surgical metastasectomy for resectable metastatic osteosarcoma.

NCT ID: NCT06070259 Not yet recruiting - Bone Cancer Clinical Trials

Insights Into Participating in Studies for Bone Cancer

Start date: October 2024
Phase:
Study type: Observational

Clinical studies, with a distinct focus on bone cancer, play a crucial role in evaluating the safety and effectiveness of novel treatments for this disease. These trials serve as instrumental means to determine whether new medications surpass conventional therapies, providing substantial evidence for their broader adoption. The primary objective is to meticulously scrutinize trial completion rates and voluntary withdrawals within this specific patient group.

NCT ID: NCT06068075 Recruiting - Ewing Sarcoma Clinical Trials

Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD

Start date: May 8, 2018
Phase: N/A
Study type: Interventional

This is a prospective multicenter biomarker study evaluating the prognostic impact of ctDNA detection at diagnosis in patients with Ewing sarcoma or osteosarcoma.